In January 2023, the U.S. FDA approved Jaypirca (pirtobrutinib) for the treatment of adults with relapsed or refractory mantle cell lymphoma who had previously undergone two lines of systemic…
Editor's Note: We believe that patients are a key part of developing and leading the conversation in disease communities. Patient Worthy sometimes partners with reputable agencies that wish to speak…
Rare Community Profiles Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families,…
Also known as Richter’s Transformation, Richter syndrome is a rare and aggressive complication of chronic lymphocytic leukemia (CLL). When someone develops Richter syndrome, their CLL can transform into another rare…
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
Accutar Biotechnology, Cranbury, New Jersey recently announced via BioSpace that dosing has begun with the first patient enrolled in the Phase 1 trial of AC0676 a chimeric degrader molecule…
According to a story from Medpage Today, a study conducted by scientists at the University of Texas MD Anderson Cancer Center highlighted the substantial benefits of aerobic exercise in people…
At the start of October 2022, biopharmaceutical company Mustang Bio, Inc. shared via news release that the first patient was treated in a study of MB-106. Within the study,…
The most common form of leukemia in Western countries is chronic lymphocytic leukemia (CLL). The disease accounts for almost thirty percent of known leukemia cases. Approximately 30,000 Europeans were…
On May 26, 2022, biopharmaceutical company Nurix Therapeutics, Inc. ("Nurix") shared via news release that positive data was available from an ongoing Phase 1a dose escalation study. Within the study,…
According to a press release that can be found on AP News, new data have been released on a potential treatment - called NVG-111 - for both mantle cell lymphoma…
Roger Bliss, 68-year-old pulmonary hypertension (PH) patient, was diagnosed with chronic lymphocytic leukemia and small lymphocytic lymphoma. In addition, Roger has celiac disease. He recently interviewed with Pulmonary Hypertension News.…
The FDA has just announced that they are reevaluating their approvals for Ukoniq. This reevaluation comes after study findings which demonstrated there may be an increased risk of fatality for…
A recent study examined the impact of age on clinical outcomes for patients diagnosed with chronic lymphocytic leukemia (CLL). This study was published in the journal Blood Advances. All patients in…
Targeted Oncology recently featured a discussion by Dr. Jennifer Brown, director of Dana Farber’s Chronic Lymphocytic Leukemia Center, on the interim results from the SEQUOIA Phase 3 trial. The trial…
Dr. Deborah M. Stephens from the Huntsman Cancer Institute recently presented at the 39th Annual Chemotherapy Foundation Symposium Innovative Cancer Therapy for Tomorrow (CFS). The presentation surrounded how critical identifying…
According to a recent article, a study looking at an investigational BTK degrader proved to have important results in patients with chronic lymphocytic leukemia. Chronic Lymphocytic Leukemia (CLL) Chronic lymphocytic…
According to a news release from biotechnology company LAVA Therapeutics N.V. ("LAVA"), the company's therapeutic candidate LAVA-051 recently earned Orphan Drug designation from the FDA. The therapy is designed for…
The 2021 Society for Hematological Oncology (SOHO) Annual Meeting took place last month from September 8-11, 2021. During the meeting, researchers discussed new advances in the field of hematology. According…
Meghan Thompson, a doctor and 3rd year fellow at Memorial Sloan Kettering Cancer Center has recently explained all of the emerging treatments using BTK inhibitors to treat CLL, chronic lymphocytic…
Having a rare, chronic disease can impact one's life significantly, whether it's physically, spiritually, socially, or psychologically. Not only this, but those responsible for these patients' care are affected as…
A better comprehension of one's cancer can provide improved treatment outcomes. It's easier to fight something that one understands. That's why a recent article published in Medical Xpress is so…
TG Therapeutics has been developing ublituximab as a treatment for chronic lymphocytic leukemia (CLL) when used in combination with umbralisib, marketed as UKONIQ. The biopharmaceutical company has recently completed and…
According to a recent news release, the FDA cleared an Investigational New Drug (IND) application for VIP152, a potential therapeutic option for patients with Richter syndrome and relapsed/refractory chronic…
In a recent press release, biopharmaceutical company AstraZeneca announced that its drug CALQUENCE (acalabrutinib) met both its primary and secondary endpoints in the Phase 3 ELEVATE-RR clinical trial. These endpoints…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
